CANADIAN PHOTODISINFECTION TECHNOLOGY HEADS TO CHINA

Photodisinfection may soon be a vital part of the Chinese medical system thanks to a recent joint venture between Vancouver-based Ondine Biomedical Inc. and Zhengzhou Zhenghe Medical Devices Co., Ltd. and Henan Yifan Technology Company Ltd. and  Canada Tidybio Science and Technology Co. Ltd.

In making the announcement, Carolyn Cross, Chair of the Board and CEO of Ondine Biomedical, says the joint venture is huge – not only because of the size of the Chinese market, but it is a strategically important initiative to combat the growing antibiotic issues the world is facing.

“With antibiotic resistance a major worldwide concern, our ground breaking – and proven — technology (now in use at two British Columbia hospitals) provides rapid antimicrobial efficacy without encouraging the formation and spread of antibiotic resistance.”

In a published Fact Sheet (#194), the World Health Organization lists antimicrobial resistance an increasingly serious threat to global public health that requires action across all government sectors and society.

The joint venture with Positive and Medical devices CO., Ltd of Zhengzhou, will have exclusive rights to two Ondine photodisinfection products – Periowave™ and MRSAid™ – for the Chinese market.

Antimicrobial resistance is resistance of a microorganism to an antimicrobial drug that was originally effective for treatment of infections. Resistant microorganisms (including bacteria, fungi, viruses and parasites) are able to withstand attack by antimicrobial drugs, such as antibacterial drugs (e.g. antibiotics), antifungals, antivirals, and antimalarials, so that standard treatments often become ineffective and infections persist, increasing the risk of spread to others.

The evolution of resistant strains occurs when microorganisms replicate themselves erroneously or when resistant traits are exchanged between them. The use and misuse of antimicrobial drugs accelerates the emergence of drug-resistant strains. Poor infection control practices, inadequate sanitary conditions and inappropriate food handling encourage the further spread of antimicrobial resistance.

New resistance mechanisms emerge and spread globally threatening the ability to treat common infectious diseases, resulting in death and disability of individuals who until recently could continue a normal course of life. Without effective anti-infective treatment, many standard medical treatments may fail or turn into very high-risk procedures.

Infections caused by resistant microorganisms often fail to respond to the standard treatment, resulting in prolonged illness, higher health care expenditures, and a greater risk of death.

As an example, the death rate for hospital patients with serious infections caused by common bacteria can be about twice that of patients with infections caused by the same non-resistant bacteria.

For example, people with MRSA (methicillin-resistant Staphylococcus aureus, another common source of severe infections in the community and in hospitals) are estimated to be 64 per cent more likely to die than people with a non-resistant form of the infection.

Ondine Biomedical Inc. is a world leader in the development of non-antibiotic, anti-infective therapies for a broad spectrum of bacterial, viral and fungal infections. Ondine is focused on the development and commercialization of its patented light activated technology – photo-disinfection. This technology provides rapid antimicrobial efficacy without encouraging the formation and spread of antibiotic resistance.

Ondine currently has numerous applications of its photodisinfection technology at various stages of development. The company’s lead product is the MRSAid™ nasal decolonization system, which is used to decolonize the nares of methicillin-resistant Staphylococcus aureus (MRSA). Other medical applications and next generation products in the hospital acquired infection market are currently under development.

Photodisinfection was first commercialized in April 2006 when Ondine launched Periowave™, an adjunctive therapy for the treatment of chronic adult periodontitis (gum disease) now available across Canadian dental offices.  MRSAid™ technology, in hospitals in BC and Ontario, is soon expecting clearance for the European market.  Vancouver General Hospital (VGH), Canada’s largest acute care hospital which has been deploying MRSAid™ since 2010, currently has the lowest surgical infection rates of any tertiary hospital in Canada.

Ondine started expanding to international markets in 2015. The company was present in the biggest medical exhibitions: Medica – Germany and Arab Health – UAE.

-end-

Media Contacts:

Carolyn Cross
604-669-0555
ccross@ondinebio.com

Karen Meohas
604-669-0555 ext. 230
kmeohas@ondinebio.com